StackTerminal.Health

BETA
Alternative layoutGrade B · 84Clean

Research-only: Recovery / Joints (BPC-157 + TB4)

Groups the two most commonly paired research peptides discussed in injury-repair circles; evidence is largely preclinical & not athlete-RCT grade.

What this is for
General support
recovery, joints, research-only
Why you are seeing this
Goal fit: recovery, joints, research-only.
What to do next
Add body metrics if you want dose previews to reflect your weight rather than the reference dose.
← BackView current layout
Buy stack
Public•Built 06 Feb 2026•2 ingredients•No interactions detected
Core stack
The main ingredients doing the work.
2 key items
BPC-157Low
PLACEHOLDER • Lyophilized •
Preclinical tissue-repair signals; limited human evidence.
Buy ingredient →
1mg
Safety / pharmacokinetics
Low
Population: Healthy volunteers
Study type: Registered phase 1 trial (results not posted)
Dose context: — • Duration: See registry

A phase 1 safety/PK study in healthy volunteers was registered; results were not posted & the submission was canceled per later reviews, limiting interpretability.

Citation: ClinicalTrials.gov NCT02637284 — PCO-02 Safety and Pharmacokinetics Trial•https://clinicaltrials.gov/study/NCT02637284
Soft tissue healing signals (preclinical)
Low
Population: Animal models (multiple tissues)
Study type: Review (preclinical-focused)
Dose context: —

Multiple preclinical models report improvements in healing-related endpoints; translation to humans remains unproven.

Citation: Cushman et al., Local and Systemic Peptide Therapies for Soft Tissue Healing (2024)•https://pmc.ncbi.nlm.nih.gov/articles/PMC11426299/
Musculoskeletal healing (preclinical)
Low
Population: Animal injury models (multiple tissues)
Study type: Narrative review of preclinical evidence
Dose context: —

Across animal models, BPC-157 is frequently reported to improve healing-related outcomes (tendon/ligament/muscle/bone & GI injury models), but translation to humans remains unproven.

Citation: Vasireddi et al., (2025) — Emerging Use of BPC-157 in Orthopaedic Sports Medicine (review)•https://pmc.ncbi.nlm.nih.gov/articles/PMC12313605/
TB500 (TB4 / Thymosin Beta-4)Low
PLACEHOLDER • Lyophilized •
Wound-healing biology (mostly preclinical); not validated as an athlete recovery protocol.
Buy ingredient →
1mg
Wound healing (clinical development)
Low
Population: Patients with venous stasis ulcers
Study type: Registered phase 2 trial (TB4 gel)
Dose context: — • Duration: Up to 84 days (per registry)

TB4 gel has been studied in venous stasis ulcer indications; registry evidence supports clinical testing, though effect sizes depend on the specific trial & endpoint reporting.

Citation: ClinicalTrials.gov NCT00832091 — Thymosin Beta 4 in Venous Stasis Ulcers•https://clinicaltrials.gov/study/NCT00832091
Wound healing
Low
Population: Rat full-thickness wound model
Study type: Preclinical animal study
Dose context: —

TB4 accelerated wound healing endpoints in a rat model compared with controls.

Citation: Malinda et al., J Invest Dermatol (1999)•DOI: 10.1046/j.1523-1747.1999.00708.x•https://pubmed.ncbi.nlm.nih.gov/10469335/
Wound healing (reviewed clinical context)
Low
Population: Stasis and pressure ulcer clinical programs
Study type: Review article
Dose context: —

A review summarizes phase 2 wound-healing programs reporting faster healing in those that did heal; note that these are not sports injury RCTs.

Citation: Treadwell et al., Ann N Y Acad Sci (2012) — The regenerative peptide thymosin β4 accelerates the rate of dermal healing•https://pubmed.ncbi.nlm.nih.gov/23050815/
Stack pre-check
No personal data connected — connect wearables or upload bloodwork for a personalised check
Clean
Supplements
2
Training load
Unknown
No flags
No duplication, stimulant, interaction, or recovery concerns detected.

Pre-check is rule-based, not medical advice. Consult a healthcare professional for personalised guidance.

Interaction Analysis
Pharmacokinetic + pair-level checks
Timing optimizations
BPC-157
Take ~1h before the intended effect window
Reaches peak plasma concentration in ~1h. Half-life ~4h.
TB500 (TB4 / Thymosin Beta-4)
Take ~1h before the intended effect window
Reaches peak plasma concentration in ~1h. Half-life ~4h.

Interaction analysis is based on peer-reviewed pharmacology. PMID links go to PubMed. Not medical advice.

Similar community stacks

If this is close but not quite right, start from a similar stack rather than from zero.

Browse all community stacks →
recoveryskinresearch-only

Research-only: Recovery + Skin (GLOW-style grouping)

by@athlete

Adds a copper peptide often discussed in cosmetic/skin contexts to a recovery/joint pairing. Evidence is indirect & component-based.

BPC-157
1mg
TB500 (TB4 / Thymosin Beta-4)
1mg
GHK-Cu
1mg
New
View
gutdigestionresearch-only

Research-only: Gut / Inflammation (KPV + BPC-157)

by@athlete

Groups gut-inflammation oriented peptides (mostly studied in preclinical colitis/inflammation models).

KPV
1mg
BPC-157
1mg
Magnesium (Glycinate)
400mg
New
View
sleepcalmfocus

Research-only: Calm + Focus (Selank + Semax)

by@athlete

Non-stimulant cognitive/calm pairing commonly discussed in nootropic communities.

Selank
1mg
Semax
10mg
New
View